Search results
Results from the WOW.Com Content Network
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis [9] and prurigo nodularis. [10]
The UK's Medicines and Healthcare Regulatory Agency (MHRA) warned of some new and severe eye-related side effects following the use of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's ...
The most common side effects across indications include injection site reactions, conjunctivitis, conjunctivitis allergic, arthralgia, oral herpes and eosinophilia. Adverse events more commonly observed with Dupixent (≥5%) compared to placebo in either COPD trial were back pain, COVID-19, diarrhea, headache and nasopharyngitis.
AEs more commonly observed with Dupixent (≥5%) compared to placebo included injection site reactions (12% vs. 4%), accidental overdose (7% vs. 3%) and COVID-19 infection (8% vs. 5%). Detailed results from this trial will be provided to the U.S. Food and Drug Administration by year-end 2024 in response to the additional data requested for ...
Ophthalmic drug administration is the administration of a drug to the eyes, most typically as an eye drop formulation. Topical formulations are used to combat a multitude of diseased states of the eye. These states may include bacterial infections, eye injury, glaucoma, and dry eye. [ 1 ] However, there are many challenges associated with ...
Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT syndrome) is a rare headache disorder that belongs to the group of headaches called trigeminal autonomic cephalalgia (TACs). [1] Symptoms include excruciating burning, stabbing, or electrical headaches mainly near the eye and typically these sensations ...
About Dupixent Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type-2 inflammation in phase 3 studies, establishing that ...
Sanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U ...